Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-Adenosyl-L-homoselenocysteine is an experimental small molecule and a selenium-containing analog of S-adenosyl-L-homocysteine (SAH). It belongs to the class of 5'-deoxyribonucleosides, specifically characterized by the replacement of the sulfur atom in the homocysteine moiety of SAH with a selenium atom. In biological systems, SAH is a potent competitive inhibitor of S-adenosyl-L-methionine (SAM)-dependent methyltransferases. Consequently, S-adenosyl-L-homoselenocysteine is primarily utilized as a biochemical research tool to investigate transmethylation pathways and the structural biology of methyltransferase enzymes. There is currently no evidence of clinical development, sponsoring pharmaceutical companies, or specific therapeutic indications for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on s-adenosyl-l-homoselenocysteine.